GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Hicin Pharmaceutical Co Ltd (SZSE:300584) » Definitions » COGS-to-Revenue

Nanjing Hicin Pharmaceutical Co (SZSE:300584) COGS-to-Revenue : 0.14 (As of Mar. 2025)


View and export this data going back to 2017. Start your Free Trial

What is Nanjing Hicin Pharmaceutical Co COGS-to-Revenue?

Nanjing Hicin Pharmaceutical Co's Cost of Goods Sold for the three months ended in Mar. 2025 was ¥19.8 Mil. Its Revenue for the three months ended in Mar. 2025 was ¥142.6 Mil.

Nanjing Hicin Pharmaceutical Co's COGS to Revenue for the three months ended in Mar. 2025 was 0.14.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Nanjing Hicin Pharmaceutical Co's Gross Margin % for the three months ended in Mar. 2025 was 86.09%.

Nanjing Hicin Pharmaceutical Co COGS-to-Revenue Historical Data

The historical data trend for Nanjing Hicin Pharmaceutical Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Hicin Pharmaceutical Co COGS-to-Revenue Chart

Nanjing Hicin Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.19 0.25 0.19 0.17

Nanjing Hicin Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.14 0.19 0.17 0.14

Nanjing Hicin Pharmaceutical Co COGS-to-Revenue Calculation

Nanjing Hicin Pharmaceutical Co's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=84.981 / 504.36
=0.17

Nanjing Hicin Pharmaceutical Co's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=19.842 / 142.649
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Hicin Pharmaceutical Co  (SZSE:300584) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Nanjing Hicin Pharmaceutical Co's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 19.842 / 142.649
=86.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Nanjing Hicin Pharmaceutical Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Nanjing Hicin Pharmaceutical Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Hicin Pharmaceutical Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Hicin Pharmaceutical Co Ltd (SZSE:300584) » Definitions » COGS-to-Revenue
Comparable Companies
SZSE:301509 SHSE:603998 SZSE:002644 SZSE:002728 SHSE:600829 SZSE:301089 SZSE:300158 SZSE:300111 SHSE:600479 SZSE:000919 ZTS XTER:MRK LSE:HLN NSE:SUNPHARMA TSE:4502 XSWX:GALD XSWX:SDZ NSE:DIVISLAB HKSE:03692 XTAE:TEVA
Traded in Other Exchanges
N/A
Address
Heng Road 1, Nanjing Economic and Technological Development Zone, Jiangsu Province, Nanjing, CHN, 210009
Website
http://www.hicin.cn
Nanjing Hicin Pharmaceutical Co Ltd is a China-based company engaged in producing pharmaceutical preparations. In addition, it is also involved in manufacturing synthetic chemicals, conducting new drug research and development as well as technical transferring. The company produces series of the medicines such as antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for the cardio-cerebral system and immuno-modulate agents. The active pharmaceutical ingredients, omeprazole sodium for injection, cefepime hydrochloride for Injection and lansoprazole tablets are exported by the firm into South-Asian countries, South-American countries and European countries.
Executives
Cao Yu Ping Directors, executives
Yan Mei Qiang Directors, executives
Jiang Xiang Ming Executives
Gu Hai Independent director

Nanjing Hicin Pharmaceutical Co Headlines

No Headlines